Ascendis Pharma (ASND) Reports Q3 Loss of EUR1.04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks rally, crude prices fall
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Crypto stocks rise premarket as Bitcoin hits over seven-month high
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- FortuneX and WT Realty announce $600M merger deal
Ascendis Pharma A/S Reports Third Quarter 2017 Financial Results
November 16, 2017 4:01 PM EST- Phase 3 Program for TransCon Growth Hormone Advances and TransCon PTH Enters the Clinic -
- Conference Call Today at 4:30 p.m. Eastern Time -
COPENHAGEN, Denmark, Nov. 16, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced financial results for the quarter ended September 30, 2017.
We are making progress every day towards achieving our Vision 20/20 strategic plan to establish Ascendis as a... More
